Chong Kun Dang Applies for Domestic Approval of CKD-701 to MFDS
[Asia Economy Reporter Minji Lee] Chong Kun Dang announced on the 28th that it has applied for domestic product approval of CKD-701 (Lucentis biosimilar) to the Ministry of Food and Drug Safety.
Hot Picks Today
"Could I Also Receive 370 Billion Won?"... No Limit on 'Stock Manipulation Whistleblower Rewards' Starting the 26th
- Samsung Electronics Labor-Management Reach Agreement, General Strike Postponed... "Deficit-Business Unit Allocation Deferred for One Year"
- "From a 70 Million Won Loss to a 350 Million Won Profit with Samsung and SK hynix"... 'Stock Jackpot' Grandfather Gains Attention
- "Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
The company stated, "CKD-701 is a biosimilar to Lucentis and has secured equivalence through quality, non-clinical, and clinical trials," adding, "it is intended for the treatment of neovascular age-related macular degeneration, and after product approval, it will enter the domestic ophthalmology treatment market.”
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
